$19.52
0.23[1.19%]
At close: May 3
$19.52
0[0.00%]
After Hours: 4:04PM EDT
Edgewise Therapeutics
(NASDAQ:EWTX)Edgewise Therapeutics Stock (NASDAQ:EWTX), Analyst Ratings, Price Targets, Predictions
Edgewise Therapeutics Inc has a consensus price target of $27.29, established from looking at the 24 latest analyst ratings. The last 3 analyst ratings were released from RBC Capital, Truist Securities, and Wedbush on April 22, 2024, April 17, 2024, and April 16, 2024. With an average price target of $27.67 between RBC Capital, Truist Securities, and Wedbush, there's an implied 41.73% upside for Edgewise Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
Truist Securities
Wedbush
Piper Sandler
JP Morgan
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Edgewise Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/22/2024 | EWTX | Buy Now | Edgewise Therapeutics | $19.52 | 63.93% | RBC Capital | Leonid Timashev | $28 → $32 | Maintains | Outperform | Get Alert |
| 04/17/2024 | EWTX | Buy Now | Edgewise Therapeutics | $19.52 | 28.07% | Truist Securities | Srikripa Devarakonda | $25 → $25 | Maintains | Buy | Get Alert |
| 04/16/2024 | EWTX | Buy Now | Edgewise Therapeutics | $19.52 | 33.2% | Wedbush | Laura Chico | → $26 | Reiterates | Outperform → Outperform | Get Alert |
| 03/12/2024 | EWTX | Buy Now | Edgewise Therapeutics | $19.52 | 43.44% | RBC Capital | Leonid Timashev | → $28 | Reiterates | Outperform → Outperform | Get Alert |
| 03/07/2024 | EWTX | Buy Now | Edgewise Therapeutics | $19.52 | 145.9% | Piper Sandler | Yasmeen Rahimi | → $48 | Initiates | → Overweight | Get Alert |
| 11/10/2023 | EWTX | Buy Now | Edgewise Therapeutics | $19.52 | 17.83% | Wedbush | Laura Chico | $27 → $23 | Maintains | Outperform | Get Alert |
| 08/16/2023 | EWTX | Buy Now | Edgewise Therapeutics | $19.52 | 38.32% | Wedbush | Laura Chico | → $27 | Reiterates | Outperform → Outperform | Get Alert |
| 08/11/2023 | EWTX | Buy Now | Edgewise Therapeutics | $19.52 | 38.32% | Wedbush | Laura Chico | → $27 | Reiterates | Outperform → Outperform | Get Alert |
| 06/30/2023 | EWTX | Buy Now | Edgewise Therapeutics | $19.52 | 28.07% | JP Morgan | Tessa Romero | $24 → $25 | Maintains | Overweight | Get Alert |
| 06/28/2023 | EWTX | Buy Now | Edgewise Therapeutics | $19.52 | 28.07% | Truist Securities | Srikripa Devarakonda | → $25 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2023 | EWTX | Buy Now | Edgewise Therapeutics | $19.52 | 43.44% | RBC Capital | Leonid Timashev | → $28 | Reiterates | Outperform → Outperform | Get Alert |
| 06/27/2023 | EWTX | Buy Now | Edgewise Therapeutics | $19.52 | 28.07% | Truist Securities | Srikripa Devarakonda | → $25 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | EWTX | Buy Now | Edgewise Therapeutics | $19.52 | 22.95% | JP Morgan | Tessa Romero | $25 → $24 | Maintains | Overweight | Get Alert |
| 05/12/2023 | EWTX | Buy Now | Edgewise Therapeutics | $19.52 | 38.32% | Wedbush | Laura Chico | → $27 | Reiterates | Outperform → Outperform | Get Alert |
| 05/01/2023 | EWTX | Buy Now | Edgewise Therapeutics | $19.52 | 28.07% | Truist Securities | Srikripa Devarakonda | → $25 | Initiates | → Buy | Get Alert |
| 02/28/2023 | EWTX | Buy Now | Edgewise Therapeutics | $19.52 | 28.07% | JP Morgan | Tessa Romero | $27 → $25 | Maintains | Overweight | Get Alert |
| 11/04/2022 | EWTX | Buy Now | Edgewise Therapeutics | $19.52 | 48.57% | RBC Capital | Leonid Timashev | $31 → $29 | Maintains | Outperform | Get Alert |
| 08/25/2022 | EWTX | Buy Now | Edgewise Therapeutics | $19.52 | -74.39% | Goldman Sachs | Madhu Kumar | → $5 | Downgrade | Neutral → Sell | Get Alert |
| 05/24/2022 | EWTX | Buy Now | Edgewise Therapeutics | $19.52 | -74.39% | Goldman Sachs | Madhu Kumar | $8 → $5 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Edgewise Therapeutics (EWTX)?
The latest price target for Edgewise Therapeutics (NASDAQ: EWTX) was reported by RBC Capital on April 22, 2024. The analyst firm set a price target for $32.00 expecting EWTX to rise to within 12 months (a possible 63.93% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Edgewise Therapeutics (EWTX)?
The latest analyst rating for Edgewise Therapeutics (NASDAQ: EWTX) was provided by RBC Capital, and Edgewise Therapeutics maintained their outperform rating.
When was the last upgrade for Edgewise Therapeutics (EWTX)?
There is no last upgrade for Edgewise Therapeutics.
When was the last downgrade for Edgewise Therapeutics (EWTX)?
The last downgrade for Edgewise Therapeutics Inc happened on August 25, 2022 when Goldman Sachs changed their price target from N/A to $5 for Edgewise Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Edgewise Therapeutics (EWTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Edgewise Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Edgewise Therapeutics was filed on April 22, 2024 so you should expect the next rating to be made available sometime around April 22, 2025.
Is the Analyst Rating Edgewise Therapeutics (EWTX) correct?
While ratings are subjective and will change, the latest Edgewise Therapeutics (EWTX) rating was a maintained with a price target of $28.00 to $32.00. The current price Edgewise Therapeutics (EWTX) is trading at is $19.52, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.